Modelli di dati selezionati

Devi effettuare il log in per selezionare i modelli di dati da scaricare per successive analisi

49 Risultati di ricerca.
rilevanza Valutazione Più recente Meno recente

Study completion-Lab Stem-Cell Transplantation CASLAMB NCT00148148

- 17/09/21 - 1 modulo, 11 itemgroups, 46 elementi, 2 lingue
Itemgroups: Documentation Date, Electrolytes, Metabolism, liver, Pancreas, Kidney, Infection, Coagulation (optional), Hematology, Hematology (optional, absolute values), Urine screening status
A Study of Caspofungin, Liposomal Amphotericin B or the Combination of Both for Patients After Stem-Cell Transplantation NCT00148148

Eligibility Stem Cell Transplantation NCT00822770

- 15/09/21 - 1 modulo, 2 itemgroups, 17 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin; ODM derived from: https://clinicaltrials.gov/show/NCT00822770

Eligibility NCT00148148 # Stem-Cell Transplantation - Eligibility

- 13/04/21 - 1 modulo, 3 itemgroups, 51 elementi, 2 lingue
Itemgroups: Inclusion criteria, Exclusion criteria, Medical Concepts
The study compares the safety, efficacy and pharmacokinetics of caspofungin, liposomal amphotericin B or the combination of both in the antifungal treatment of adult patients after allogeneic haematopoietic stem-cell transplantation with granulocytopenia and persistent i.g. recurrent fever under adequate antibacterial therapy.

Eligibility Lymphoma NCT00113646

- 13/04/21 - 1 modulo, 2 itemgroups, 12 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies; ODM derived from: https://clinicaltrials.gov/show/NCT00113646

Eligibility Stem Cell Transplantation NCT00813124

- 04/11/18 - 1 modulo, 2 itemgroups, 18 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML); ODM derived from: https://clinicaltrials.gov/show/NCT00813124

Master Data Pediatric Hematology and Oncology UK Muenster

- 15/12/16 - 1 modulo, 3 itemgroups, 36 elementi, 2 lingue
Itemgroups: Medical history, Complications, recurrent disease
Freigabe zur Verarbeitung durch Frau Prof. Rössig, Quellenangabe: "Pädiatrische Hämatologie und Onkologie, UKM" Klinik für Kinder- und Jugendmedizin, Universitätsklinikum Münster Released for adaption by Frau Prof. Rössig Source:Pediatric Hematology und Oncology, University hospital Münster

Master Data Pediatric Hematology and Oncology UK Muenster

- 15/12/16 - 1 modulo, 3 itemgroups, 34 elementi, 2 lingue
Itemgroups: Medical history, Complications, recurrent disease
Freigabe zur Verarbeitung durch Frau Prof. Rössig, Quellenangabe: "Pädiatrische Hämatologie und Onkologie, UKM" Klinik für Kinder- und Jugendmedizin, Universitätsklinikum Münster Released for adaption by Frau Prof. Rössig Source:Pediatric Hematology und Oncology, University hospital Münster

100 days past HSCT EBMT Follow up - 100 days past HSCT EBMT

- 25/09/16 - 1 modulo, 13 itemgroups, 129 elementi, 1 linguaggio
Itemgroups: Classification, HSCT - Minimum Essential Data - A First report - 100 days after HSCT DISEASE CLASSIFICATION SHEET 2, CHRONIC MYELOGENOUS LEUKAEMIA (CML) (main disease code 2) Note: CMML is not a CML, OTHER LEUKAEMIAS (main disease code 2), HSCT - Minimum Essential Data – A First report - 100 days after HSCT DISEASE CLASSIFICATION SHEET 3, HSCT - Minimum Essential Data - A First report - 100 days after HSCT DISEASE CLASSIFICATION SHEET 4, HSCT - Minimum Essential Data - A First report - 100 days after HSCT DISEASE CLASSIFICATION SHEET 5, HSCT - Minimum Essential Data - A First report - 100 days after HSCT DISEASE CLASSIFICATION SHEET 6, HSCT - Minimum Essential Data - A First report - 100 days after HSCT DISEASE CLASSIFICATION SHEET 7, BONE MARROW FAILURE SYNDROMES including APLASTIC ANAEMIA (main disease code 7)ISMC, HSCT - Minimum Essential Data - A First report - 100 days after HSCT DISEASE CLASSIFICATION SHEET 8, HSCT - Minimum Essential Data - A First report - 100 days after HSCT DISEASE CLASSIFICATION SHEET 9, HSCT - Minimum Essential Data - A First report - 100 days after HSCT DISEASE CLASSIFICATION SHEET 10
ODM form derived from 100days past HSCT EBMT. please refer to: http://www.ebmt.org/Contents/Data-Management/Registrystructure/MED-ABdatacollectionforms/Pages/MED-AB-data-collection-forms.aspx HLA typing results of patient and donor should be attached and sent: - to your NATIONAL REGISTRY if - you normally report to your National Registry and - you are based in the Netherlands, Switzerland, Turkey or the UK - to the EBMT REGISTRY OFFICE in London for any other centre Contact: Shelley Hewerdine EBMT Registry Office 4th Floor, Tabard House Guy's Hospital Great Maze Pond London SE1 9RT United Kingdom Phone: 00 44-207-188-8409 Fax: 00 44-207-188-8411 Email: shelley.hewerdine@ebmt.org

Eligibility Leukemia NCT00027560

- 24/07/16 - 1 modulo, 2 itemgroups, 16 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00027560

18pp EBMT Amyloidosis

- 07/06/16 - 1 modulo, 21 itemgroups, 424 elementi, 1 linguaggio
Itemgroups: GENERAL INFORMATION TEAM, GENERAL INFORMATION PATIENT, DISEASE, AL AMYLOIDOSIS INITIAL DIAGNOSIS, ORGAN INVOLVEMENT AT DIAGNOSIS, PRE-HSCT TREATMENT, HSCT, STATUS OF DISEASE AT COLLECTION (AUTOGRAFTS ONLY), STATUS OF DISEASE AT START OF CONDITIONING FOR BMT, STATUS OF DISEASE AT 100 DAYS AFTER HSCT, ORGAN-SPECIFIC RESPONSES AT 100 DAYS AFTER HSCT, FORMS TO BE FILLED IN, FOLLOW UP AL AMYLOIDOSIS, PATIENT LAST SEEN, GRAFT VERSUS HOST DISEASE (GvHD) SINCE LAST REPORT, OTHER COMPLICATIONS SINCE LAST REPORT, GRAFT ASSESSMENT AND HAEMOPOIETIC CHIMAERISM, ADDITIONAL THERAPIES SINCE LAST FOLLOW UP, FIRST EVIDENCE OF DISEASE WORSENING SINCE LAST HSCT, LAST DISEASE AND PATIENT STATUS, ADDITIONAL NOTES IF APPLICABLE
DOCUMENTED PATHOGENS (Use this table for guidance on the pathogens of interest) Bacteria: S. pneumoniae, Other gram positive (i.e.: other streptococci, staphylococci, listeria …),Haemophilus influenzae, Other gram negative (i.e.: E. coli klebsiella, proteus, serratia, pseudomonas …), Legionella sp, Mycobacteria sp, Other Fungi: Candida sp, Aspergillus sp, Pneumocystis carinii, Other Parasites: Toxoplasma gondii, Other Viruses: HSV, VZV, EBV, CMV, HHV-6, RSV. Other respiratory virus (influenza, parainfluenza, rhinovirus), Adenovirus, HBV, HCV, HIV,Papovavirus, Parvovirus, Other

Analysis of chimerism after SCT AML - Department of Internal Medicine Knappschaftskrankenhaus Bochum-Langendreer - Analysis of Chimerism after SCT AML

- 10/02/16 - 1 modulo, 3 itemgroups, 13 elementi, 1 linguaggio
Itemgroups: Patient data, Findings, Diagnosis

Eligibility Multiple Myeloma NCT00781170

- 24/01/16 - 1 modulo, 2 itemgroups, 19 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Dose-Reduced Allogeneic Stem Cell Transplantation After Autologous High-Dose Chemotherapy in Patients With Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT00781170

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial